Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Stem Cell Targeting and Overcoming Chemoresistance.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ALDH1A1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ALDH1A1 Active Enzyme / Mutant Protein (WT & Catalytic Mutant). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW confirmed. | View ALDH1A1 Products |
| Gene Delivery | ALDH1A1 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. HEK293 Expressed. | View ALDH1A1 Products |
| Benchmark Ab | Anti-ALDH1A1 Monoclonal Antibody. Recombinant positive control for IHC/Western. | View ALDH1A1 Products |
| Validator | ALDH1A1 siRNA Set (3 unique sequences). For knockdown verification and specificity controls. | View ALDH1A1 Products |
| Isoform Selectivity Panel | ALDH1A3 Recombinant Protein. Close isoform for selectivity screening (CSC marker). | View ALDH1A3 Products |
| Safety Counter-screen | ALDH2 Recombinant Protein. Mitochondrial isoform; critical off-target toxicity assessment. | View ALDH2 Products |
| Related Target A | ALDH1A2. Crucial counter-screening homolog to avoid off-target toxicity in retinoic acid pathways. | View ALDH1A2 Products |
| Related Target B | CD44. Key cancer stem cell (CSC) co-marker for synergistic targeting and flow cytometry validation. | View CD44 Products |
Critical Assay Challenges and TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Subfamily Counter Screening (ALDH1A2/ALDH1A3/ALDH2) | Homolog panel proteins strictly verified by mass spec, maintaining theoretical MW and active tetrameric conformation. Matched isoform panel >95% purity. |
| Intracellular Target Accessibility & Compound Penetration | Lentivirus-mediated stable cell line construction tools for precise cellular turnover assays; premade lentivirus particles. |
| Lack of Validated Assays for Resistance / Catalytic Mechanism Validation | Expression vectors for mutant profiling; sequence-verified active-site mutant proteins (Cys302Ser catalytic-dead) for mechanistic control. |
| False Positives in HTS / Off-target Binding | High-purity enzyme preparations (>95%) with strict endotoxin control (<1EU/µg); Validated siRNA included for specificity checks; negative control isoforms available. |
| Enzymatic Activity Preservation | HEK293 Expressed (proper folding); Endotoxin Controlled to prevent cellular assay interference. |
| Benchmark Detection & CSC Quantification | High-specificity detection antibody (IHC-grade) included. |
Live ALDH1A1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ALDH1A1 therapeutics is intensifying, with major players shifting focus from broad-spectrum chemotherapy to precision elimination of Cancer Stem Cells (CSCs). ALDH1A1 drives multidrug resistance by detoxifying chemotherapeutic agents (e.g., cyclophosphamide) and shielding reactive oxygen species (ROS), making it a central node in refractory solid tumors (ovarian, breast, lung, and prostate). First-generation pan-ALDH inhibitors faced safety limitations due to ALDH2 cross-reactivity (ethanol metabolism disruption). The next wave of R&D is targeting highly selective allosteric inhibitors and emerging intracellular modalities like PROTACs. As clinical pipelines advance, combination therapies with chemo/immunotherapy and diagnostic co-development are gaining traction.
Competitive Modality & Indication Snapshot
| Modality | Representative Focus/Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic Hubs / CSC Biotechs; Bayer, Otsuka | Refractory Solid Tumors (Breast/Ovarian), Acute Myeloid Leukemia | Isoform Selectivity Assays (Need pure, active ALDH1A1 vs ALDH1A2/A3/ALDH2 panels) |
| PROTACs / Targeted Degradation | Preclinical Discovery; Emerging biotech | Pan-cancer (Resistance bypass), Solid Tumors | Degradation & Ubiquitination Assays (Need recombinant intracellular target pools; Lentivirus for stable overexpression lines) |
| Combination Therapies | Pharma + Standard of Care Chemo | Chemo-resistant relapse settings | Synergy Validation (Need stable overexpression cell lines via Lentivirus) |
| Diagnostic IHC | Abbott, Roche | Prognostic CSC markers (Breast, Lung, Liver) | Positive Control Antibodies (Sequence verified recombinant mAbs) |